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Abstract
Background: Genital warts are one of the most common forms of sexually-transmitted disease, but their
epidemiology has yet to be thoroughly elucidated. The present study was designed to shed light on the
prevalence of clinically-confirmed, self-reported genital warts (GWs) in a representative sample of the university
population.
Methods: In 2015, a cross-sectional survey was conducted on 11,096 individuals approached at the Students
Information Bureau where they came to enroll for a university degree course. Participants completed an
anonymous, self-administered questionnaire providing information on their sociodemographic characteristics, sexual
behavior, and any history of clinically-diagnosed genital warts. Multivariate logistic regression was then used to
identify any factors associated with the disease.
Results: Our analysis was conducted on 9259 questionnaires (83.4%). Participants were a mean 21.8 ± 4.8 years of
age, and 59.6% were female. Overall, 124 individuals (1.3%, 95%CI: 1.0–1.6) reported having been diagnosed with
genital warts: 48 men (1.3%, 95%CI: 0.9–1.6), and 76 women (1.4% 95%CI: 1.1–1.7). Overall, 22.5% of the sample
were vaccinated (1.3% of the males and 36.8% of the females). The group of respondents aged 30 years or more
had the highest incidence of genital warts (males: 5.6%, 95%CI: 2.5–8.6; females: 6.9%, 95%CI: 3.4–10.4). The
independent risk factors associated with a history of disease were (for both genders) a history of other sexually-
transmitted diseases, and ≥2 sex partners in the previous 24 months. A protective role emerged for routine
condom use. Additional risk factors associated with genital warts in males concerned men who have sex with men,
bisexuality vis-à-vis heterosexuality, and smoking.
Conclusions: The findings emerging from our study help to further clarify the epidemiology of genital warts in
young people, and may be useful to public health decision-makers. This study showed that genital warts occur in
men as well as women, and suggests that both genders should be monitored for this disease to ascertain the
effects of the free HPV vaccination offered to all girls in the Veneto in their 12th year of life since 2008, and to all
boys of the same age since 2015.
Keywords: Genital warts, Human papillomavirus, Sexually-transmitted diseases
* Correspondence: vincenzo.baldo@unipd.it
1Department of Cardiac, Thoracic and Vascular Sciences, Public Health Unit,
University of Padua, Padua, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cocchio et al. BMC Infectious Diseases  (2018) 18:41 
DOI 10.1186/s12879-018-2954-7
Background
Genital warts (GWs) are classified as a clinical form of hu-
man papillomavirus (HPV) infection because they are vis-
ible lesions in the form of single or multiple papules
developing in the area of the vulva, perineum, anus, va-
gina, cervix, penis, scrotum and urethra [1, 2]. The clinical
symptoms of GWs include pruritus, burning sensation,
vaginal discharge, and bleeding [3]. More than 90% of
these lesions are associated with HPV types 6 and 11,
which usually give rise to benign changes, though they are
sometimes associated with malignancies [4]: from 20% to
50% of HPV-related lesions have revealed not only HPV-6
and -11, but also co-infections with other HPV types car-
rying a high oncogenic risk [4, 5]. Genital warts are often
not considered a serious problem, and few studies have
been conducted on the quality of life of patients with these
lesions. On the other hand, several reports have men-
tioned the negative psychological effects of this disease,
such as stress, embarrassment and anxiety, which are
sometimes persistent [6–10].
Genital warts are one of the most common sexually-
transmitted diseases (STD), occurring particularly among
young people of both genders [11]. In surveys conducted
on general adult populations, the self-reported lifetime his-
tory of GWs ranged from 0.36% to 12% in women [12–15],
and from 0.27% to 7.9% in men [12, 16]. A history of GWs
in the previous 12 months was reported by 1.0% to 1.9% of
females in the 4 Nordic countries [13].
Australia, the USA and several countries in Europe
have introduced HPV vaccination programs for girls
with a view to the prevention of cervical cancer [6]. The
targets of quadrivalent HPV vaccine are HPV types 6,
11, 16 and 18, so it has the potential to protect against
GWs as well as precancerous lesions and malignancies
in both genders [17–19].
In the Veneto region (north-east Italy), free quadriva-
lent HPV vaccination has been offered to all girls in their
12th year of life since 2008, and in 2015 the program
was extended to include boys in their 12th year of life
too. HPV vaccine remains freely accessible to these co-
horts up until they turn 18 years old. It is also offered
on a co-payment basis to women up until they are
46 years of age, and to men until they are 26 years old.
The paucity of data concerning the epidemiology of
GWs in Italy prompted the present study, which was de-
signed to estimate the prevalence of clinically-confirmed,
self-reported GWs in a sexually-active university popula-
tion and to pinpoint any risk factors associated with the
disease.
Methods
Study population
A cross-sectional study on GWs was conducted at the
University of Padua, Italy, between September and
November 2015. The study population included individ-
uals (with an age ≥ 18 years old) going to the Students
Information Bureau to enroll for a university degree
course.
Data collection
A self-administered anonymous printed questionnaire
were offered to each participant. To ensure confidentiality,
participants were asked to seal their completed question-
naires in an envelope they were given at the same time.
The questionnaire covered several lifestyle factors, in-
cluding sociodemographics (e.g. marital status, formal
education), smoking, alcohol intake, condom use, sexual
habits (e.g. age at time of first sexual intercourse, num-
ber of sex partners in the previous 2 years).
Information on GWs was obtained with the question,
‘Have you ever had genital warts diagnosed by a doctor
or other health care professional?’ There were also ques-
tions on how long the episode(s) of GWs lasted and
whether any had occurred in the previous 12 months.
Details of any other sexually-transmitted infections, such
as Chlamydia trachomatis, herpes simples, human im-
munodeficiency virus, syphilis or gonorrhea, were also
requested.
Respondents who reported never having had sexual
intercourse were excluded from the analysis.
Statistical analysis
The recruiting target to obtain a precision in excess of
0.5% was estimated to be about 11,000 students, based
on the assumption of 10% of non-responders and a
prevalence of GWs of around 1.5%.
Descriptive statistics (including means and proportions
for continuous variables, and percentages and absolute
frequencies for categorical variables) were used to
analyze the data by gender and age group (18–20 years,
21–24 years, 25–29 years, and 30+ years). The preva-
lence of GWs was estimated as the proportion of re-
spondents who reported a clinically-confirmed diagnosis
of GW at some time in their lives. The χ2 test, Student’s
t-test, and 95% confidence intervals (CI95%) were used,
as appropriate. Factors independently associated with
the experience of GWs were examined using a multivari-
ate logistic regression, from which adjusted ORs were
estimated with corresponding 95% CIs. A p value < 0.05
was adopted as the threshold for statistical significance.
Results
During the study, 11,096 of the individuals approached
agreed to complete the questionnaire. After they were
checked for completeness and data quality, 10,049 ques-
tionnaires (90.6%) were included; 790 subjects (7.9%)
were excluded because they reported never having had
sexual intercourse. The study population consisted in
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Table 1 Characteristics of 9259 respondents stratified by gender
Variables Males Females Total
(N. 3742) (N. 5517) (N. 9259)
Age groups [n (%)]
18–20 1735 (46.4) 2771 (50.2) 4506 (48.7)
21–24 1477 (39.5) 2197 (39.8) 3674 (39.7)
25–29 314 (8.4) 346 (6.3) 660 (7.1)
30+ 216 (5.8) 203 (3.7) 419 (4.5)
Age at time of first sexual intercourse (mean ± SD)
18–20 16.9 (1.2) 16.7 (1.3) 16.8 (1.3)
21–24 17.3 (1.8) 17.2 (1.8) 17.2 (1.8)
25–29 17.9 (2.3) 17.8 (2.3) 17.8 (2.3)
30+ 18.5 (3.5) 18.4 (2.7) 18.5 (3.1)
Sex partners in the last 24 months [n (%)]
≤ 1 2579 (68.9) 4218 (76.5) 6797 (73.4)
≥ 2 1163 (31.1) 1299 (23.5) 2462 (26.6)
Relationship [n (%)]
exclusive 1497 (40.0) 3187 (57.8) 4684 (50.6)
not exclusive 506 (13.5) 477 (8.6) 983 (10.6)
single 1739 (46.5) 1853 (33.6) 3592 (38.8)
Sexual orientation [n (%)]
heterosexual 3535 (94.5) 5188 (94.0) 8723 (94.2)
homosexual 112 (3.0) 67 (1.2) 179 (1.9)
bisexual 95 (2.5) 262 (4.7) 357 (3.9)
Other sexually-transmitted infections [n (%)]
no 3627 (96.9) 5249 (95.1) 8876 (95.9)
yes 115 (3.1) 268 (4.9) 383 (4.1)
Condom use [n (%)]
no 594 (15.9) 1547 (28.0) 2141 (23.1)
occasionally 647 (17.3) 922 (16.7) 1569 (16.9)
yes 2318 (61.9) 2783 (50.4) 5101 (55.1)
not specified 183 (4.9) 265 (4.8) 448 (4.8)
Smoking [n (%)]
no 2479 (66.2) 3878 (70.3) 6357 (68.7)
ex-smoker 366 (9.8) 399 (7.2) 765 (8.3)
yes 897 (24.0) 1240 (22.5) 2137 (23.1)
Alcohol intake [n (%)]
No 491 (13.1) 1113 (20.2) 1604 (17.3)
occasionally 3030 (81.0) 4312 (78.2) 7342 (79.3)
Every day 221 (5.9) 92 (1.7) 313 (3.4)
HPV vaccination [n (%)]
18–20 33 (0.9) 1473 (26.7) 1506 (16.3)
21–24 12 (0.3) 515 (9.3) 527 (5.7)
25–29 2 (0.1) 40 (0.7) 42 (0.5)
30+ 2 (0.1) 3 (0.1) 5 (0.1)
Cocchio et al. BMC Infectious Diseases  (2018) 18:41 Page 3 of 8
9259 subjects, with a majority of females (59.6%). Partic-
ipants were a mean 21.8 ± 4.8 years old (22.2 ± 5.7 for
males, 21.4 ± 4.0 for females), and the vast majority
(95.5%) were between 18 and 29 years old.
Table 1 shows the characteristics of the sample ana-
lyzed by gender. In 50.6% of cases, the respondents re-
ported being in an exclusive relationship (men were less
likely to do so than women, p < 0.001). Women were less
likely than men to be single (33.6% vs 46.5%, respect-
ively; p < 0.001). In 55.1% of the questionnaires the re-
spondent reported using condoms. Among the female,
35.2% were using hormonal contraceptives. Our respon-
dents reported having been a mean 17.3 ± 1.7 years old
for men, and 17.3 ± 1.6 years for women (p = n.s.) at the
time of their first sexual intercourse. The youngest age
group considered (18- to 20-year-olds) had been younger
at the time (16.8 years old) than the other age groups
(18.5 years old for the respondents over thirty; p < 0.05).
The mean number of sex partners in the previous
24 months was 1.3 ± 1.4 for the women, and 1.9 ± 2.3 for
the men (p < 0.001). Sexually-transmitted infections
other than genital warts were reported by 4.9% of the
women and 3.1% of the men (p < 0.001). Overall, 22.8%
of the sample reported having been vaccinated against
HPV (1.3% of the males, and 36.8% of the females).
Overall, 124 respondents (1.3%, 95%CI: 1.0–1.6) re-
ported having been diagnosed with GWs at some time;
48 of them were men (1.3%, 95%CI: 0.9–1.6) and 76
were women (1.4%, 95%CI: 1.1–1.7). Of these 124 cases
of GWs, 33 had reportedly occurred in the previous
12 months (15 cases in males, 18 in females). The epi-
sodes of GWs had lasted for a mean 3.9 ± 2.3 months,
with 50% of cases cured within 3 months, 29% within
6 months, and 21% taking longer than six months.
The mean age at the time of answering the question-
naire, and the mean number of sex partners in the
previous 24 months were both significantly higher
among the individuals who had experienced episodes of
GWs (the GW group) than among those who had not
(the no-GW group). The mean age of the GW group
was 25.8 ± 8.0 years, as opposed to 21.7 ± 4.7 years for
the no-GW group (p < 0.01). There was no statistically
significant gender-related difference in the mean age of
the respondents in the GW group (26.6 ± 8.2 years for
men, 25.3 ± 7.9 for women). As for the mean number of
sex partners, this was reportedly 3.2 ± 3.6 in the GW
group, as opposed to 1.6 ± 1.8 in the no-GW group (p <
0.01). The mean age of the GW group at the time of
their first sexual intercourse was younger than in the
no-GW group (16.8 ± 1.8 vs 17.1 ± 1.7 years, respectively;
p < 0.05). A clear pattern emerged in the likelihood of a
history of GWs with increasing age (p < 0.01). In both
genders, the respondents over 30 years old had the high-
est proportion in the GW group (5.6%, 95%CI: 2.5–8.6
for males; and 6.9%, 95%CI: 3.4–10.4 for females); the
difference between men and women was not statistically
significant. Fig 1 shows the rates of clinically-confirmed,
self-reported GWs by gender and age.
In the GW group the mean number of sex partners in
the previous 24 months was significantly higher for
males than for females (3.2 ± 3.6 vs 1.6 ± 1.8, respect-
ively; p < 0.05). As for sexuality, there were significantly
more males than females (p < 0.05) who reported being
homosexual or bisexual. Males were also significantly
more likely than females (p < 0.05) to be smokers.
GWs were significantly less frequent in females who
were vaccinated than in those who were not (0.6% versus
1.8%; OR 0.35 (0.19–0.64), while in males there was no
significant difference between the two (Tables 2 and 3).
The multivariate analysis showed that, for both gen-
ders, the independent variables associated with a history
of GWs were: age (adjusted OR 1.05 [1.01–1.09] in
Fig. 1 Lifetime incidence rate of self-reported genital warts by gender and age group
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males, 1.10 [1.06–1.13] in females); ≥2 sex partners in
the previous 24 months (adjusted OR 3.58 [1.63–7.88] in
males, 1.92 [1.09–3.36] in females); a history of sexual
infections other than GWs (adjusted OR 8.20 [3.95–
17.2] in males, 5.72 [3.23–10.1] in females); while rou-
tine condom use had a protective role (adjusted OR 0.40
[0.18–0.88] in males, and 0.47 [0.25–0.91] in females).
For males, additional factors independently associated
with GWs were a sexuality other than heterosexuality,
and smoking (Table 2), while in females there was a
protective role of vaccination (adjusted OR 0.50 [0.26–
0.96] (Table 3).
Discussion
In this survey of university students (a selected popula-
tion), comprising more than 10,000 young men and
women (who were a mean 21.8 years old), the lifetime
prevalence of clinically-confirmed, self-reported, GWs
was similar between the genders, with an overall 1.3% in
males and 1.4% in females. In a US population aged 18–
Table 2 Univariate and multivariate analysis of self-reported genital warts in males
Variables Number
of
subjects
GWs OR Adj OR
N (%) (95% CI) (95% CI)
Age [continuous variable] 3742 48 (1.3) 1.10 (1.07–1.13) 1.05 (1.01–1.09)
Age at time of first sexual intercourse
[continuous variable]
0.88 (0.76–1.02) 0.96 (0.81–1.13)
Sex partners in the last 24 months
≤ 1 2579 14 (0.5) reference
≥ 2 1163 34 (2.9) 5.52 (2.95–10.3) 3.58 (1.63–7.88)
Relationship
exclusive 1497 22 (1.5) reference
not exclusive 506 11 (2.2) 1.49 (0.72–3.09) 0.97 (0.40–2.36)
single 1739 15 (0.9) 0.58 (0.27–1.28) 0.69 (0.30–1.55)
Sexual orientation
heterosexual 3535 31 (0.9) reference
homosexual 112 10 (8.9) 11.0 (5.30-23.1) 8.88 (3.70-21.3)
bisexual 95 7 (7.4) 8.99 (3.3-24.5) 5.16 (1.88-14.1)
Positive history of
sexually-transmitted infections
no 3627 32 (0.9) reference
yes 115 16 (13.9) 18.1 (9.69–34.0) 8.20 (3.95–17.0)
Vaccination status
no 3693 47 (1.3) reference
yes 49 1 (2.0) 1.62 (0.22–11.9) 1.87 (0.21–16.4)
Condom use
no 594 17 (2.9) reference
occasionally 647 13 (2.0) 0.70 (0.34–1.45) 0.69 (0.30–1.60)
yes 2318 18 (0.8) 0.27 (0.13–0.55) 0.40 (0.18–0.88)
not specified 183 0 (0.0) –
Smoking (reference: no)
no 2479 12 (0.5) reference
ex-smoker 366 13 (3.6) 7.57 (3.43–16.7) 6.11 (2.47–15.1)
yes 897 23 (2.6) 5.41 (2.71–10.8) 4.60 (2.05–10.3)
Alcohol intake
no 491 12 (2.4) reference
occasionally 3030 30 (1.0) 0.40 (0.20–0.78) 0.30 (0.13–0.69)
yes 221 6 (2.7) 1.11 (0.46–2.70) 0.35 (0.11–1.11)
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59 years, the prevalence of a positive history of GWs
was 7.2% for women, and 4% for men [15]; in a sample
population aged 16–55 years in the Czech Republic, the
figures were 6.1% and 5.8% in women and men, respect-
ively [20]; in a population aged 18–45 years in Estonia,
they were 4.6% and 2.8%, respectively [21, 22]; and in
Denmark the figures were higher, at 10.6% in women
and 7.9% in men [13]. The results of other studies on
women of similar age placed their lifetime prevalence of
GWs at 12% in Iceland, 11.3% in Sweden, and 9.5% in
Norway [13]. The prevalence identified in our popula-
tion was low by comparison with the above-mentioned
studies, probably because our sample was still very
young (95.5% of respondents were between 18 and
29 years old). In fact, our analysis identified a rising
trend in the positive history of GWs with age in both
Table 3 Univariate and multivariate analysis of self-reported genital warts in females
Variables Number
of
subjects
GWs OR Adj OR
N (%) (95% CI) (95% CI)
Age [continuous variable] 5517 76 (1.4) 1.06 (1.03–1.09) 1.10 (1.06–1.13)
Age at time of first sexual intercourse [continuous variable] 0.94 (0.78–1.12) 0.89 (0.77–1.02)
Sex partners in the last 24 months
≤ 1 4218 41 (1.0) reference
≥ 2 1299 35 (2.7) 2.82 (1.79–4.45) 1.92 (1.09–3.36)
Relationship
exclusive 3187 41 (1.3) reference
not exclusive 477 11 (2.3) 1.81 (0.92–3.55) 1.76 (0.81–3.82)
single 1853 24 (1.3) 1.01 (0.49–2.07) 1.30 (0.72–2.35)
Sexual orientation
heterosexual 5188 70 (1.3) reference
homosexual 67 1 (1.5) 1.11 (0.15-8.09) 0.81 (0.11-6.19)
bisexual 262 5 (1.9) 1.42 (0.16-12.4) 0.70 (0.24-2.02)
Positive history of sexually-transmitted infections
no 5249 55 (1.0) reference
yes 268 21 (7.8) 8.03 (4.79–13.5) 5.72 (3.23–10.1)
Vaccination status
no 3486 63 (1.8) reference
yes 2031 13 (0.6) 0.35 (0.19–0.64) 0.50 (0.26–0.96)
Condom use
no 1547 32 (2.1) reference
occasionally 922 21 (2.3) 1.10 (0.63–1.92) 0.93 (0.49–1.77)
yes 2783 23 (0.8) 0.39 (0.22–0.72) 0.47 (0.25–0.91)
not specified 265 0 (0.0) –
Smoking (reference: no)
no 3878 45 (1.2) reference
ex-smoker 399 8 (2.0) 1.74 (0.82–3.72) 0.92 (0.39-2.20)
yes 1240 23 (1.9) 1.61 (0.71–3.63) 0.91 (0.51-1.62)
Alcohol intake
no 1113 17 (1.5) reference
occasionally 4312 55 (1.3) 0.83 (0.48–1.44) 1.04 (0.54–1.99)
yes 92 4 (4.3) 2.93 (1.04–8.26) 1.35 (0.37–4.85)
Oral contraceptive use
No 3577 28 (0.8) reference
yes 1940 28 (1.4) 1.86 (1.1–3.14) 1.10 (0.63–1.92)
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genders, which peaked at 5.6% and 6.9% in males and fe-
males, respectively, among our respondents over 30 years
old (the difference between genders was not statistically
significant), reaching figures more similar to those of
other studies [13, 15, 20–22]. Other reasons contributing
to our lower prevalence may relate to methodological
differences (e.g. study design), and to geographical and
cultural differences in sexual behavior. In our study
population, there was also evidence of the respondents
who were younger at the time of answering our ques-
tionnaire having been younger when they first had sex-
ual intercourse.
For both genders, the two factors most strongly associ-
ated with the risk of developing GWs were a history of
other sexual infections and ≥2 sex partners in the previ-
ous 24 months, as seen in other studies [13, 15, 20–23].
Consistently with other reports [22], men who de-
scribed themselves as homosexual carried a very signifi-
cantly higher risk of developing GWs than men
reporting to be heterosexual.
In our sample, routine condom use conferred a signifi-
cant reduction in the risk of developing GWs in both
genders. This finding is consistent with a retrospective
case-control study on men and women attending the
Sydney Sexual Health Centre, with and without newly-
diagnosed GWs [24]. As for the use of hormonal contra-
ceptives, our analysis revealed no additional risk of GWs
among women using oral contraceptives. This result
contradicts the findings of a study conducted on women
with and without GWs seen at a city-center clinic for
genitourinary medicine in Scotland, which suggested
that women taking oral contraceptives may be at higher
risk of presenting with GWs [25].
The influence of smoking on the risk of acquiring
GWs is controversial. It is hard to say whether smoking
is a confounder or a genuine risk factor for GWs: some
authors found no correlation [26, 27], while our data
would seem to support other reports of a positive link
between smoking and the burden of GWs among males
[20, 22, 13, 24, 28].
Our data should be interpreted bearing in mind some
limitations of this study. We used a self-administered
questionnaire in a selected population in order to
maximize the participation rate and ensure a large sam-
ple size, but this means that the risk of selection and
interview bias cannot be ruled out (i.e. a bias due to re-
spondents under-reporting any behavioral risk factors,
for instance).
In Italy, free anti-HPV vaccination has been actively
offered to all girls in their 12th year of life since 2008,
and there has been a significant reduction in the cases of
GWs over time in the age groups for which the vaccina-
tion’s coverage had reached a good level [29]. Because
no information was available on the timing of any
self-reported HPV vaccination in our sample, it is im-
possible to say whether, or how the prevalence of
GWs identified in this study might have been influ-
enced by vaccination. Nonetheless, a protective role
of vaccination did emerge for females, probably due
to the inclusion of women who had been vaccinated
at 12 years old. In the remainder of our sample not
actively offered vaccination, it is likely that those who
reported having had a vaccination had done so be-
cause of a known risk of contracting GWs, or after
an episode of GWs.
We nonetheless judge our results to be valid and
reliable for the purpose of drawing comparisons with
other populations (self-reporting on GWs has been
used in several other studies in Europe and the USA
[15, 20–22, 13]).
To achieve a higher specificity, our question on any
history of GWs referred only to clinically confirmed
diagnoses. As a consequence, our figures may under-
estimate the real prevalence of this condition because
some respondents may have had GWs but not gone to
a doctor to confirm their diagnosis. Individuals who de-
velop GWs may have a limited capacity to recognize
them, or be unwilling or unable to seek treatment.
There are numerous psychological and social issues in-
volved, which may contribute to explaining why preva-
lence estimates tend to be higher in studies based on
clinical genital examinations [1].
Conclusion
Our study contributes to the body of knowledge on the
epidemiology of HPV-related disease among young
people. These findings may be useful to public health
decision-makers because they provide a basis for assessing
the potential burden of genital HPV that can be prevented
by vaccination programs. The present study showed that
not only women suffer from GWs, and suggests that both
genders should be monitored for the occurrence of these
lesions – also to shed light on the effects of HPV vaccin-
ation programs offered in a given region, for instance.
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